Acne Severity Endpoints for Clinical Trials
Automated inflammatory lesion counting, spatial density, an IGA-scale severity score and ALADIN for acne clinical trials, from standardised photographs of the face. CE-marked medical device.
Automated inflammatory lesion counting, spatial density, an IGA-scale severity score and ALADIN for acne clinical trials, from standardised photographs of the face. CE-marked medical device.
Evidence behind automated acne scoring, covering the peer-reviewed ALADIN study against expert dermatologists, the validation of the inflammatory lesion detector, the DIQA image quality gate, the post-market clinical follow-up, and the foundational acne references.
End-to-end clinical trial workflow for acne endpoints, covering protocol design, site setup, patient enrolment, facial image capture, automated lesion counting and ALADIN scoring, IGA success against baseline, data export, and EDC integration.
How facial images are captured for automated acne scoring: the standard two-diagonal set, DIQA quality control, patient preparation, and site standardisation.
Transparent documentation of what the AI acne severity scoring can and cannot do, including scope boundaries, the status of the clinical evidence, skin type representation, and how each limitation is managed.
How the AI scores acne from photographs of the face, covering inflammatory lesion detection, spatial density, the ALADIN formula on the IGA scale, response definitions, a worked example, and comparison with manual assessment.